The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer

The phase 2 TRADE study evaluated whether a dose-escalation strategy of adjuvant abemaciclib improves drug tolerability among patients with node-positive HR+ HER2- breast cancer.  The study met its primary endpoint, with the adjuvant abemaciclib dose-escalation strategy allowing a greater number of patients to reach and maintain the 150 mg dose at 12 weeks than in the monarchE trial.